|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Using an SGK1 inhibitor, AR(W741L) transcriptional and growth promoting activity was reduced indicating that exploiting functional distinctions between receptor isoforms in our model may provide new and effective therapies for CRPC patients.
|
26267320 |
2015 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RNA-seq data from CTCs identified mutations commonly associated with CRPC as well as novel mutations, including several in the ligand-binding domain of AR that could facilitate escape from AR-targeted agents.
|
29266182 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In prostate cancer (PC), the androgen receptor (AR) is a key transcription factor at all disease stages, including the advanced stage of castrate-resistant prostate cancer (CRPC).
|
24753418 |
2014 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, androgen receptor gene amplification and mutation are associated with PCa to develop castration-resistant prostate cancer (CRPC).
|
31062387 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Collectively, this study suggests that VT-464 therapy can effectively treat CRPC and be used in precision medicine based on androgen receptor mutation status.
|
27748439 |
2016 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, activations of the AR, PI3K, mTOR, NFκB and Hedgehog (Hh) signaling pathways are involved in the fatal development of castration-resistant prostate cancer during androgen ablation therapy.
|
24913494 |
2014 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, highly sensitive next-generation sequencing and PCR-based methods for analyzing androgen receptor gene (AR) copy numbers (CN) and mutations in plasma were established in cell-free DNA (cfDNA) of patients with castration-resistant prostate cancer (CRPC) treated with different drugs.
|
31689899 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This review will summarize AR alterations of clinical relevance for patients with CRPC, with focus on constitutively active AR variants, their possible association with <i>AR</i> amplification and structural rearrangements as well as their ability to predict patient resistance to AR targeting drugs.
|
29030409 |
2017 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, androgen receptor splice variant 7 (AR-V7) detection has been associated with worse outcomes for patients with castration-resistant prostate cancer (CRPC) treated with novel androgen receptor-signaling (ARS) inhibitors such as abiraterone and enzalutamide but not taxane chemotherapies.
|
29319382 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide.
|
31251826 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings support the development of new therapies targeting the polyadenylation signal in AR intron 3 as a strategy to prevent expression of a broad array of AR variants in CRPC.<i></i>.
|
28928128 |
2017 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SRC kinase is activated in castration resistant prostate cancer (CRPC), phosphorylates the androgen receptor (AR), and causes its ligand-independent activation as a transcription factor.
|
26091350 |
2015 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
|
28373004 |
2017 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Blocking lipid/cholesterol synthesis in AR variants-expressing CRPC cell line and xenograft models markedly reduces tumor growth through inhibition of mTOR pathway.
|
29059155 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Role of an androgen receptor gene polymorphism in development of hormone refractory prostate cancer in Indian population.
|
17696745 |
2008 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Androgen receptor (AR) splice variants (ARVs) are implicated in development of castration-resistant prostate cancer (CRPC).
|
29309643 |
2018 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Constitutively active androgen receptor splice variants (AR-V) lacking the ligand-binding domain have been implicated in the pathogenesis of castration-resistant prostate cancer and in mediating resistance to newer drugs that target the androgen axis.
|
26060018 |
2015 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We established a highly sensitive method for analyzing androgen receptor gene (AR) copy numbers (CN) and mutations in plasma circulating cell-free DNA (cfDNA) and evaluated the AR statuses of patients with CRPC.
|
30858508 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Predicting treatment response in castration-resistant prostate cancer: could androgen receptor variant-7 hold the key?
|
25547524 |
2015 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It was also among the first small molecules shown to directly inhibit the activity of AR splice variants (ARVs), which has important clinical implications in the treatment of castration-resistant prostate cancer.
|
30873507 |
2019 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The androgen receptor splice variant-7 (AR-V7) has been implicated in the development of castration-resistant prostate cancer (CRPC) and resistance to abiraterone and enzalutamide.
|
27117751 |
2016 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
PTEN deletion is common in HRPC, with bi-allelic loss correlating to disease-specific mortality and associated with Akt and AR deregulation.
|
19402094 |
2009 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations.
|
27255944 |
2016 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CNVs of AR and CYP17A1 genes would appear to be associated with outcome of CRPC patients treated with abiraterone.
|
25897673 |
2015 |
|
Hormone refractory prostate cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Proteins that physically interact with the AR, such as the ERG gene fusion product, FOXA1, MLL2, UTX (also known as KDM6A) and ASXL1 were found to be mutated in CRPC.
|
22722839 |
2012 |